Bryan Garnier - Oncimmune Holdings (ONC) ONCIMMUNE: ECLS- Diagnosing Lung Cancer Early | CORPORATE | 180p (+88%)

Report

Bryan Garnier

Ross Blair

ONCIMMUNE: ECLS- Diagnosing Lung Cancer Early | CORPORATE | 180p (+88%)

ONCIMMUNE - CORPORATE | 180p (+88%)
ECLS- Diagnosing Lung Cancer Early

Importance of ECLS Trial
ECLS Meets Primary Endpoints- The Results
Next Steps

10/09/2019 3 EN

Underlying

Oncimmune Holdings

Oncimmune Holdings and its subsidiaries are engaged in cancer diagnosis.

See profile

GB00BYQ94H38 London Stock Exchange United Kingdom

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Ross Blair

Other Reports on these Companies

Hybridan

Hybridan Small Cap Feast: 24/02/2025

Our daily digest of news from UK Small Caps @HybridanLLP 24th February 2025 * A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication Dish of the day Admissions: Delistings: Argo Group (ARGO.L) left AIM today. On Friday 21st February, both Deltex Medical (DMG.L) and Tribe Technology (...

February 24, 2025 February 24, 2025 1 EN

Hardman & Co

Hardman & Co Monthly: January 2025

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets. Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from profitability. Despite this, some companies can still make extremely attractive returns for investors. ...

January 10, 2025 January 10, 2025 1 EN

Hardman & Co

Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector. The HHI fell 17.7% to 398.9, underperforming all its benchmarks – FTSE 100 (+5.7%), FTSE All-Share (5.6%) and the FTSE AIM All-Share Index (-5.7%). Only 11 companies in our index saw share prices rise in 2024. Despite challenges in raising ne...

January 9, 2025 January 9, 2025 1 EN

Fastned: H1 results, GM recovery, roll-out acceleration expected in H2

This morning, Fastned published its H1 2025 key metrics and number of operating stations. H1 sales came in at EUR54.3m (+44% YoY), implying revenue of EUR26.3m in Q2 2025 (-9% vs cons. at EUR28.9m) and pointing to an annual run-rate of at least EUR108m (vs cons. at EUR130.8m for FY25 and STFe EUR13

August 14, 2025 August 14, 2025 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Avantium: financing package update

Yesterday, Avantium announced it had reached a conditional agreement with ABN AMRO, ASN, ING, Invest-NL and Rabobank to extend and amend its senior debt facility agreement, representing up to EUR125.1m as of December 2024. As such, (i) the remaining EUR14.1m debt commitment would be cancelled in ex

August 13, 2025 August 13, 2025 1 EN

Damien Choplain ... (+2)

Damien Choplain
Oscar Haffen Lamm

Valneva : Strong H1 - Key Lyme vaccine catalyst ahead in Q4

Valneva delivered a solid H1 and reaffirmed its 2025 guidance. The company’s cash position, standing at €161m, is sufficient to fund operations through 2027e, providing solid financial visibility. Looking ahead, the next key catalyst is the Phase III data readout for VLA15, Valneva’s Lyme disease v

August 12, 2025 August 12, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN